MedTrace Logo

Ketoconazole Foam 2% for the Treatment of Versicolor

NCT00830388 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2012-08-22

Study results available
· View outcomes & findings →

Summary

Ten adult patients age 19 and older with a clinical diagnosis of tinea versicolor, as well as a positive Potassium Hydroxide (KOH) using calcofluor. Ketoconazole 2% foam will be used to determine its effectiveness, safety and satisfaction when used to treat tinea versicolor.

Conditions

  • Tinea Versicolor

Interventions

DRUG

Ketoconazole 2% Foam

Ketoconazole 2% Foam, twice daily application to affected areas for 4 weeks.

Sponsors & Collaborators

  • Boni Elewski, MD

    lead OTHER

Principal Investigators

  • Boni E Elewski, MD · University of Alabama at Birmingham

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2010-08-31
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00830388 on ClinicalTrials.gov